ALK and non-small cell lung carcinoma: ,11 Atezolizumab is an anti-PD-L1 monoclonal antibody approved as monotherapy or in combination with chemotherapy for first-line treatment of advanced NSCLC with no EGFR or ALK genomic tumor aberrations.6